TKL Research is Building New Clinical Research Facility in Fair Lawn, N.J.
News Jun 20, 2013
TKL Research is constructing a new clinical research facility in Fair Lawn, N.J., that will include a 30-bed, Phase 1 unit as well as multiple, outpatient clinical examination rooms.
The new facility, which will also give the company an expanded capability for conducting the full range of dermatological safety studies for which it has a particular expertise, will join three other TKL Research clinics in northern New Jersey as part of the company’s Research Clinics Division.
In addition to its leading dermatology capabilities, TKL Research has deep expertise in the areas of gastroenterology, respiratory, endocrinology and women’s health and significant experience in global clinical studies for pharmaceutical, medical device, nutritional and consumer health care companies.
The company offers a full range of clinical trial management services, from strategy and protocol development to biostatistics, medical writing and regulatory submission.
“The Fair Lawn research facility will enable us to meet the increased demand for our services in the diseased-state populations for Phase 1 clinical trials in which we have strong patient recruitment expertise,” said TKL Research President and CEO Jon C. Anderson, Ph.D.
The new facility also complements the company’s Clinical Trials Division, based in Rochelle Park, N.J., which provides a full-service capability in the clinical trial management of international, multicenter Phase 2-4 studies.
Founded more than 60 years ago, TKL Research moved its CRO operations to Rochelle Park, N.J., in 2006, and expanded its European capabilities with clinical operations in Münster, Germany, in 2010.
“These moves, as well as the construction of our new facility in Fair Lawn, will help us continue to deliver exceptional services to our clients that give them a competitive edge and accelerated enrollment,” Anderson said.
Anderson continued, “We’re able to work with sponsors and investigators to accelerate enrollment of high-quality study participants, and, through our comprehensive management services, we deliver strong expertise in a comprehensive range of CRO services over a wide geographic area.”
The TKL Research Fair Lawn facility is expected to be operational early next year.
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE